Valeo Pharma Inc. (CSE:VPH, OTCQB:VPHIF) has told investors that its two innovative asthma therapies, Atectura Breezhaler and Enerzair Breezehaler have been accepted for reimbursement by the Ontario Drug Benefit program, the Manitoba Pharmacare Program, the New Brunswick Drug plan, and the Non-Insured Health Benefits (NIHB) and Veterans Affairs Canada (VAC) federal programs.
The Kirkland, Quebec-headquartered company noted that the public reimbursments are now in effect except for the Ontario listing which takes effect on February 28, 2022.
The listings are now published on the Ontario Drug Benefit Formulary, the Manitoba Drug Benefits Formulary and New Brunswick Drug Plans Formulary, it added.
READ: Valeo Pharma reveals a major milestone for its two innovative asthma therapies with reimbursements approved
"With the addition of Ontario, Manitoba, New Brunswick, NIHB and VAC to our existing list of provincial/federal public listings, public reimbursement now covers over 80% of the Canadian population suffering from chronic asthma thereby improving their access to these two innovative medications," Valeo's president and chief operating officer Frederic Fasano said in a statement.
"Securing extensive public and private reimbursement was part of our roadmap to build a fast-growing respiratory business unit."
Valeo said it is now working with the remaining provincial authorities in Canada to secure their public reimbursement to continue making asthma control a more attainable goal for all Canadian asthma patients.
Public coverage in these jurisdictions also means that private payers that follow public plans will now cover both drugs. Private coverage for Enerzair and Atectura now exceeds 90% of privately covered lives across Canada, the company added.
Valeo Pharma is dedicated to the commercialization of innovative prescription products in Canada with a focus on respirology, neurodegenerative diseases, oncology and other specialty products.
The company has the complete infrastructure to register and properly manage its growing product portfolio through all stages of commercialization.
Contact the author at stephen.gunnion@proactiveinvestors.com